Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Inmune Bio Inc (NQ: INMB ) 8.355 +0.555 (+7.12%) Streaming Delayed Price Updated: 1:45 PM EDT, Jul 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Inmune Bio Inc < Previous 1 2 Next > INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial June 27, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. to Join Russell 3000® Index May 30, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9 May 07, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years April 30, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer April 29, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules April 25, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay April 23, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering April 22, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024 April 08, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28 March 26, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy March 13, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™ March 05, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference February 12, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024 February 06, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program January 30, 2024 From INmune Bio, Inc. Via GlobeNewswire ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology January 16, 2024 ELEVAI Labs to commercialize use of proprietary technology designed to produce high-quality, cGMP grade mesenchymal stromal cells at lower-cost From Elevai Labs Inc. Via GlobeNewswire INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer January 02, 2024 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA December 18, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium November 29, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease November 27, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe November 15, 2023 The Company received regulatory approval to extend its Phase II trial of XPro™ in individuals with early Alzheimer’s disease in Poland, with additional European Union (EU) countries expected to open... From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority October 31, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα October 30, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference October 17, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1 October 16, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference September 07, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’s Disease September 05, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference August 01, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7 July 31, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference. July 12, 2023 From INmune Bio, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
